Foley Partner Mark Waxman was quoted in an article titled “What impact will Obama administration have on human subjects research?” in the February 1, 2010 issue of IRB Advisor. Waxman discusses proposed changes to the health care industry under the Obama administration, stating that a possible change would be the lifting of the ban on federal funding of stem cell research and an increase in the number of stem cell trials. He adds that two bills to watch are the Fair Access to Clinical Trials act, which would strengthen a national data base of clinical trials information, and the Physician Payments Sunshine Act of 2008, which calls for transparency in physician relationships with pharmaceutical and device companies.
Related News
January 15, 2026
In the News
Kyle Faget Assesses Regulatory Shifts Impacting Medtech
Foley & Lardner LLP partner Kyle Faget is featured in four Medtech Insight articles evaluating the medtech industry’s major developments in 2025 and examining 2026 regulatory challenges.
January 14, 2026
In the News
James Lundy on Stakes for Securities Industry as Disgorgement Case Heads to SCOTUS
Foley & Lardner LLP partner James Lundy addressed the impact a ruling from the U.S. Supreme Court would have on the securities industry in the Law360, “SEC To Lean On Congress As Defense In High Court Case.”
January 14, 2026
In the News
Natasha Allen on Companies Navigating AI Regulations – 'The issue right now is timing'
Foley & Lardner LLP partner Natasha Allen shared insight on how companies are navigating AI regulations in the Silicon Valley Business Journal article, “Silicon Valley companies navigate AI adoption as state and federal rules remain uncertain.”